. The total ion chromatogram and MS spectra of plasma phospholipids. HPLC-MS analysis (A) and MS spectra of phosphatidylethanolamine (PE) (B), phosphatidylinositol (PI) (C), phosphatidylcholine (PC) (D), sphingomyelin (SM) (E), lysophosphatidylethanolamine (LPE) (F), and lysophosphatidylcholine (LPC) (G). Figure S3 . Changes in the ratio of phospholipids depending on sample amount. The ratios of phospholipids do not change significantly when analyzed in 25 µL, 50 µL, or 100 µL of plasma. Figure S4 . Flow chart for study design and biomarker selection procedure. Unstable phospholipid species and minor species were excluded from analysis (*, quantifiable and stable species; **, significantly different between the two group (p < 0.05); cancer, n = 20; benign ovarian tumors (benign), n = 20; and healthy, non-cancer pathology (control), n = 22).
